MA33917B1 - Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue - Google Patents

Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue

Info

Publication number
MA33917B1
MA33917B1 MA35055A MA35055A MA33917B1 MA 33917 B1 MA33917 B1 MA 33917B1 MA 35055 A MA35055 A MA 35055A MA 35055 A MA35055 A MA 35055A MA 33917 B1 MA33917 B1 MA 33917B1
Authority
MA
Morocco
Prior art keywords
cycle
carboxylic acid
acid derivatives
substituted oxazolopyrimidine
oxazolopyrimidine
Prior art date
Application number
MA35055A
Other languages
Arabic (ar)
English (en)
Inventor
Dieter Kadereit
Matthias Schaefer
Stephanie Hachtel
Axel Dietrich
Thomas Huebschle
Katrin Hiss
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33917B1 publication Critical patent/MA33917B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La présente invention concerne des composés d'oxazolopyrimidine de la formule (i) dans laquelle a, r1, r2, r3 et x sont définis comme indiqués dans les revendications. Les composés de la formule (i) conviennent par exemple pour la cicatrisation de plaies.
MA35055A 2010-01-14 2011-01-12 Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue MA33917B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305042 2010-01-14
PCT/EP2011/050301 WO2011086079A1 (fr) 2010-01-14 2011-01-12 Dérivés d'acide carboxylique comprenant un noyau d'oxazolopyrimidine à substitution en 2,5

Publications (1)

Publication Number Publication Date
MA33917B1 true MA33917B1 (fr) 2013-01-02

Family

ID=41800578

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35055A MA33917B1 (fr) 2010-01-14 2011-01-12 Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue

Country Status (31)

Country Link
US (1) US8846692B2 (fr)
EP (1) EP2523962B1 (fr)
JP (1) JP5841067B2 (fr)
KR (1) KR101759128B1 (fr)
CN (1) CN102791717B (fr)
AR (1) AR079997A1 (fr)
AU (1) AU2011206615B2 (fr)
BR (1) BR112012017437B1 (fr)
CA (1) CA2784560C (fr)
CL (1) CL2012001972A1 (fr)
CO (1) CO6612239A2 (fr)
CY (1) CY1115055T1 (fr)
DK (1) DK2523962T3 (fr)
ES (1) ES2441954T3 (fr)
HK (1) HK1178885A1 (fr)
HR (1) HRP20140179T1 (fr)
IL (1) IL220720A (fr)
MA (1) MA33917B1 (fr)
MX (1) MX2012007834A (fr)
MY (1) MY156550A (fr)
NZ (1) NZ601113A (fr)
PL (1) PL2523962T3 (fr)
PT (1) PT2523962E (fr)
RS (1) RS53254B (fr)
RU (1) RU2564018C2 (fr)
SG (1) SG182484A1 (fr)
SI (1) SI2523962T1 (fr)
TW (1) TWI510242B (fr)
UY (1) UY33179A (fr)
WO (1) WO2011086079A1 (fr)
ZA (1) ZA201204174B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079980A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
AR079981A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de acido carboxilico que comprenden un anillo de oxoazolopirimidina 2,5,7- sustituido
DK2523960T3 (da) * 2010-01-14 2014-01-20 Sanofi Sa Heterocykliske carboxylsyrederivater med en 2,5-substitueret oxazolopyrimidinring
CN102834400B (zh) * 2010-01-14 2015-06-10 赛诺菲 2,5-取代的*唑并嘧啶衍生物
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
EP2862574A1 (fr) * 2013-10-15 2015-04-22 Sanofi Acide {4-[5-(3-chloro-phénoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-diméthyl-phénoxy}-acétique pour son utilisation dans la prévention ou le traitement de l'insuffisance rénale aiguë

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679682A (en) * 1970-04-23 1972-07-25 Fmc Corp CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES
JPH01242587A (ja) * 1988-03-25 1989-09-27 Sankyo Co Ltd 縮環オキサゾロチエノピリミジン誘導体
JP2006524672A (ja) * 2003-04-25 2006-11-02 ユニバーシティー・カッレッジ・カーディフ・コンサルタンツ・リミテッド ウイルス感染の治療において使用するための複素環式化合物
CA2523677A1 (fr) * 2003-04-30 2004-11-11 Novartis Ag Derives d'amino-propanol comme modulateurs de recepteur de sphingosine-1-phosphate
EP1638551B1 (fr) * 2003-05-19 2011-12-21 Irm Llc Composes immunosuppresseurs et compositions
CA2524048C (fr) * 2003-05-19 2013-06-25 Irm Llc Composes immunosuppresseurs et compositions
AU2006283175A1 (en) * 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
EP2121648A2 (fr) * 2007-03-21 2009-11-25 EPIX Pharmaceuticals, Inc. Composés modulant les récepteurs de la s1p et leur utilisation
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
EP2583720A1 (fr) * 2008-07-15 2013-04-24 Sanofi Oxazolopyrimidines en tant qu'agonistes du récepteur Edg.1
AR079980A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
AR079981A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de acido carboxilico que comprenden un anillo de oxoazolopirimidina 2,5,7- sustituido
AR079982A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5,7- sustituido., composiciones farmaceuticas y procesos para prepararlos.
CN102834400B (zh) * 2010-01-14 2015-06-10 赛诺菲 2,5-取代的*唑并嘧啶衍生物
DK2523960T3 (da) * 2010-01-14 2014-01-20 Sanofi Sa Heterocykliske carboxylsyrederivater med en 2,5-substitueret oxazolopyrimidinring

Also Published As

Publication number Publication date
IL220720A (en) 2015-02-26
CN102791717B (zh) 2016-03-30
JP5841067B2 (ja) 2016-01-06
TWI510242B (zh) 2015-12-01
MX2012007834A (es) 2012-07-30
BR112012017437B1 (pt) 2022-03-03
DK2523962T3 (en) 2014-03-10
CN102791717A (zh) 2012-11-21
US20130079358A1 (en) 2013-03-28
US8846692B2 (en) 2014-09-30
CY1115055T1 (el) 2016-12-14
RU2564018C2 (ru) 2015-09-27
CA2784560A1 (fr) 2011-07-21
UY33179A (es) 2011-08-31
CO6612239A2 (es) 2013-02-01
PL2523962T3 (pl) 2014-05-30
RU2012134630A (ru) 2014-02-20
HRP20140179T1 (hr) 2014-03-28
RS53254B (en) 2014-08-29
WO2011086079A1 (fr) 2011-07-21
MY156550A (en) 2016-02-26
CL2012001972A1 (es) 2012-10-19
BR112012017437A2 (pt) 2021-03-02
CA2784560C (fr) 2017-12-05
AU2011206615B2 (en) 2015-03-19
KR20120101732A (ko) 2012-09-14
EP2523962B1 (fr) 2013-11-27
AU2011206615A1 (en) 2012-08-02
KR101759128B1 (ko) 2017-07-18
TW201134475A (en) 2011-10-16
ZA201204174B (en) 2013-02-27
HK1178885A1 (en) 2013-09-19
AR079997A1 (es) 2012-03-07
SG182484A1 (en) 2012-08-30
IL220720A0 (en) 2012-08-30
SI2523962T1 (sl) 2014-02-28
NZ601113A (en) 2013-07-26
JP2013517241A (ja) 2013-05-16
EP2523962A1 (fr) 2012-11-21
ES2441954T3 (es) 2014-02-07
PT2523962E (pt) 2014-02-06

Similar Documents

Publication Publication Date Title
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
ME01284B (fr) Composés organiques
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA33917B1 (fr) Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
TN2013000353A1 (fr) Dérivés de fluoro-pyridinone utiles comme agents antibactériens
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA33492B1 (fr) Inhibiteurs de bace
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA201070422A1 (ru) Производные оксадиазола
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA30402B1 (fr) Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA33358B1 (fr) Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
GEP20146125B (en) Aminopyrimidines as syk inhibitors
EA201390222A1 (ru) Гетероциклическое соединение и его применение
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
MY154484A (en) Treatment of virally induces lesions
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA200802054A1 (ru) Ингибиторы фермента
EA201171211A1 (ru) Производные оксадиазола